Jan 7, 2013

Friends (332) January 7, 2013    1 Views    0 Comments SeraCare Life Sciences, a portfolio company of Linden Capital Partners, has sold its biorepository, biobanking and laboratory services business to Precision Health Holdings. The Maryland-based business includes biorepository and biobanking services and certain laboratory services. PRESS RELEASE SeraCare Life Sciences, a portfolio company of Linden Capital Partners serving the in vitro diagnostics and clinical laboratory markets, today announced that it has sold its biorepository, biobanking and laboratory services business to Precision Health Holdings, Inc. This Maryland-based business includes biorepository and biobanking services, AccuCell® products and certain laboratory services. “The sale of our Biorepository business is an important element in our growth strategy for SeraCare,” said Charles Mamrak, CEO of SeraCare. “We can now more freely serve our growing customer base in the in vitro diagnostics market and execute on our mission of improving quality of life by advancing a global understanding of disease.” The transaction includes the transfer of Biorepository assets and employees. Financial terms of the transaction were not disclosed. SeraCare Life Sciences was advised by BroadOak Partners LLC and Kirkland & Ellis LLP during the transaction. About SeraCare Life Sciences, Inc. SeraCare partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics. For more information, visit www.seracare.com. About Linden Capital Partners Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. Leave a Reply